

ADULT AMBULATORY INFUSION ORDER
Olipudase Alfa-rpcp (XENPOZYME)
Infusion

Page 1 of 3

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

This plan will expire after 365 days at which time a new order will need to be placed

GUIDELINES FOR ORDERING:

- 1. Send FACE SHEET and H&P or most recent chart note.
- 2. Severe hypersensitivity (ie, anaphylaxis, angioedema) and infusion-associated reactions have been reported with olipudase alga-rpcp. Ensure appropriate medical monitoring and support measures are available during treatment.
- 3. Treatment should be in direct consultation with a physician knowledgeable in the management of acid sphingomyelinase deficiency (ASMD).
- 4. Pregnancy status should be verified in all patients with reproductive potential prior to treatment start. Those who may become pregnant should use effective contraception during therapy and for 14 days after the last dose of olipudase alfa-rpcp.

LABS:

☐ CMP, Routine, ONCE, every

NURSING ORDERS:

- TREATMENT PARAMETER Hold treatment and contact provider for AST/ALT greater than 2x ULN
- 2. Reference rate table on MAR for dose specific infusion rates. Infusion Rates are dose specific (Initial, dose, maintenance doses). If no infusion related reactions are seen, rate increases are appropriate in 20-minute intervals as detailed on the table. Contact provider for guidance if patient has had previous infusion reaction.
- 3. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.

PRE-MEDICATIONS: (Administer 30 minutes prior to infusion)

acetaminophen (TYLENOL) tablet, 650 mg, oral, ONCE, every visit diphenhydrAMINE (BENADRYL) capsule, 25 mg, oral, ONCE, every visit. <i>Give either loratadine or</i>
diphenhydrAMINE, not both.
loratadine (CLARITIN) tablet, 10 mg, oral, ONCE, every visit, if diphenhydrAMINE is not given. <i>Give</i> either loratadine or diphenhydrAMINE, not both.
methylPREDNISolone (SOLUMEDROL), 40 mg, intravenous, ONCE, every visit



Oregon Health & Science University Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER

Olipudase Alfa-rpcp (XENPOZYME) Infusion

Page 2 of 3

ACCOUNT NO.
MED. REC. NO
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

MEDICATIONS:

Dosing weight – For patients with a BMI \leq 30 kg/m², use actual body weight. For patients with BMI > 30 kg/m², use the following adjusted body weight for dosage calculation: adjusted body weight = (actual height in meters)² × 30.

olipudase alfa-rpcp (XENPOZYME) in sodium chloride 0.9%, intravenous

- ☐ Initiation (Dose Escalation Regimen)
 - 0.1 mg/kg, ONCE (week 0)
 - 0.3 mg/kg, EVERY 2 WEEKS x 2 doses (weeks 2 and 4)
 - 0.6 mg/kg, EVERY 2 WEEKS x 2 doses (weeks 6 and 8)
 - 1 mg/kg, ONCE (week 10)
 - 2 mg/kg, ONCE (week 12)
- ☐ Maintenance (week 14 and ongoing) 3 mg/kg, EVERY 2 WEEKS

HYPERSENSITIVITY MEDICATIONS:

- NURSING COMMUNICATION If hypersensitivity or infusion reactions develop, temporarily hold the
 infusion and notify provider immediately. Administer emergency medications per the Treatment
 Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for
 symptom monitoring and continuously assess as grade of severity may progress.
- 2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 3. EPINEPHrine HCI (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction

By signing below, I represent the following: I am responsible for the care of the patient (who is identified at the top of this form); I hold an active, unrestricted license to practice medicine in: Oregon that corresponds with state where you provide care to patient and where you are currently state if not Oregon);	(check box v licensed. Specify
My physician license Number is #(MUST BE COMPLETED TO PRESCRIPTION); and I am acting within my scope of practice and authorized by law to o medication described above for the patient identified on this form.	

Printed Name: Phone: Fax:

PO-818	22
--------	----

Date/Time:

Provider signature: _____



Oregon Health & Science University Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER

Olipudase Alfa-rpcp (XENPOZYME) Infusion

Page 3 of 3

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (

OLC Central Intake Nurse:

Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient's preferred clinic location:

□ Beaverton

OHSU Knight Cancer Institute 15700 SW Greystone Court Beaverton, OR 97006

Phone number: 971-262-9000 Fax number: 503-346-8058

☐ Gresham

Legacy Mount Hood campus Medical Office Building 3, Suite 140 24988 SE Stark Gresham, OR 97030

Phone number: 971-262-9500 Fax number: 503-346-8058

□ NW Portland

Legacy Good Samaritan campus Medical Office Building 3, Suite 150 1130 NW 22nd Ave. Portland, OR 97210

Phone number: 971-262-9600 Fax number: 503-346-8058

□ Tualatin

Legacy Meridian Park campus Medical Office Building 2, Suite 140 19260 SW 65th Ave. Tualatin, OR 97062

Phone number: 971-262-9700 Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders